Industry
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
Failure Rate
33.3%
1 terminated/withdrawn out of 3 trials
Success Rate
66.7%
-19.8% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed trials have results
Key Signals
3 with results
Enrollment Performance
Analytics
Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT05574010Phase 1Terminated
A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
Role: lead
NCT06001177Phase 2Completed
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
Role: lead
NCT04248855Phase 1Completed
Assessment of KAN-101 in Celiac Disease (ACeD)
Role: lead
All 3 trials loaded